Spruce Biosciences, Inc. Common Stock Total Liabilities
Spruce Biosciences, Inc. Common Stock total liabilities. Based on the latest financial reports, Spruce Biosciences, Inc. Common Stock (SPRB) has total liabilities worth $19.12 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SPRB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Spruce Biosciences, Inc. Common Stock (2018–2025)
Total liabilities of Spruce Biosciences, Inc. Common Stock from 2018 to 2025. This chart illustrates how Spruce Biosciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Spruce Biosciences, Inc. Common Stock's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Spruce Biosciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Spruce Biosciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Basso Industry Corp
TW:1527
|
Taiwan | NT$625.95 Million |
|
Ekovest Bhd
KLSE:8877
|
Malaysia | RM8.39 Billion |
|
Fortune Information Systems Corp
TW:2468
|
Taiwan | NT$1.34 Billion |
|
Zhejiang Zone King Environmental Sci&Tech Co Ltd
SHG:688701
|
China | CN¥317.25 Million |
|
Orion Minerals Ltd
AU:ORN
|
Australia | AU$59.95 Million |
|
Vitro S.A.B. de C.V
MX:VITROA
|
Mexico | MX$965.25 Million |
|
Eastern Co
NASDAQ:EML
|
USA | $92.03 Million |
|
Daedong Ind
KO:000490
|
Korea | ₩1.82 Trillion |
Liability Composition Analysis (2018–2025)
This chart breaks down Spruce Biosciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Spruce Biosciences, Inc. Common Stock's balance sheet.
Liquidity & Leverage Metrics
Spruce Biosciences, Inc. Common Stock Total Liabilities Ratios Explained
Spruce Biosciences, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spruce Biosciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spruce Biosciences, Inc. Common Stock (2018–2025)
The table below shows the annual total liabilities of Spruce Biosciences, Inc. Common Stock from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.51 Million | -35.90% |
| 2024-12-31 | $16.39 Million | -40.27% |
| 2023-12-31 | $27.44 Million | +59.87% |
| 2022-12-31 | $17.16 Million | +13.54% |
| 2021-12-31 | $15.12 Million | +12.33% |
| 2020-12-31 | $13.46 Million | -61.91% |
| 2019-12-31 | $35.33 Million | +56.48% |
| 2018-12-31 | $22.58 Million | -- |
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more